Neuroblastoma vaccine (MabVax/MSKCC)

N/A

Report date: 2024/04/24 17:06:05

Base Information

Drug NameNeuroblastoma vaccine (MabVax/MSKCC)
Drug Alias NameMV NeuroGD2-GD3 vaccinepolyvalent prophylactic vaccine (neuroblastoma)MVNB-02
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Vaccine type > Multivalent vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A